Qian et al. developed paclitaxel (PTX)-loaded chitosan/poly(N-isopropylacrylamide) nanoparticles (NPs) for the active management and treatment of human breast cancer with KDR/Flk-1 overexpression. Here, KDR is linked to breast cancer.